ATE517873T1 - 6-oxo-1,6-dihydropyrimidin-2-yle bei der behandlung proliferativer krankheiten - Google Patents

6-oxo-1,6-dihydropyrimidin-2-yle bei der behandlung proliferativer krankheiten

Info

Publication number
ATE517873T1
ATE517873T1 AT07862644T AT07862644T ATE517873T1 AT E517873 T1 ATE517873 T1 AT E517873T1 AT 07862644 T AT07862644 T AT 07862644T AT 07862644 T AT07862644 T AT 07862644T AT E517873 T1 ATE517873 T1 AT E517873T1
Authority
AT
Austria
Prior art keywords
yle
dihydropyrimidine
oxo
treatment
proliferative diseases
Prior art date
Application number
AT07862644T
Other languages
English (en)
Inventor
Zhuoliang Chen
Run-Ming David Wang
Ming Chen
Christopher Sean Straub
Leigh Zawel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of ATE517873T1 publication Critical patent/ATE517873T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/96—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT07862644T 2006-12-07 2007-12-07 6-oxo-1,6-dihydropyrimidin-2-yle bei der behandlung proliferativer krankheiten ATE517873T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87343606P 2006-12-07 2006-12-07
PCT/US2007/025096 WO2008073305A1 (en) 2006-12-07 2007-12-07 6-oxo.-1, 6-dihydropyrimidin-2-yls in the treatment of proliferative diseases

Publications (1)

Publication Number Publication Date
ATE517873T1 true ATE517873T1 (de) 2011-08-15

Family

ID=39267989

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07862644T ATE517873T1 (de) 2006-12-07 2007-12-07 6-oxo-1,6-dihydropyrimidin-2-yle bei der behandlung proliferativer krankheiten

Country Status (15)

Country Link
US (2) US8048886B2 (de)
EP (1) EP2099769B1 (de)
JP (1) JP2010512321A (de)
KR (1) KR20090086244A (de)
CN (1) CN101535273B (de)
AT (1) ATE517873T1 (de)
AU (1) AU2007332861A1 (de)
BR (1) BRPI0720050A2 (de)
CA (1) CA2670726A1 (de)
ES (1) ES2370536T3 (de)
MX (1) MX2009005938A (de)
PL (1) PL2099769T3 (de)
PT (1) PT2099769E (de)
RU (1) RU2009125617A (de)
WO (1) WO2008073305A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010098866A1 (en) 2009-02-27 2010-09-02 Supergen, Inc. Cyclopentathiophene/cyclohexathiophene dna methyltransferase inhibitors
US20100317593A1 (en) * 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
GB201218862D0 (en) * 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
SG10201808102WA (en) 2013-12-20 2018-10-30 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
CA2950911C (en) 2014-06-04 2023-10-10 Sanford-Burnham Medical Research Institute Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy
JP6785838B2 (ja) 2015-08-05 2020-11-18 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 新規な置換グリシン誘導のｆｘｉａ阻害剤
RU2670204C1 (ru) * 2017-12-01 2018-10-19 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Производные 2-тиоурацила, обладающие противоаденовирусной активностью
WO2021026672A1 (en) 2019-08-09 2021-02-18 Novartis Ag Heterocyclic wdr5 inhibitors as anti-cancer compounds
CA3166980A1 (en) 2020-01-20 2021-07-29 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
US20230167070A1 (en) * 2020-05-01 2023-06-01 Constellation Pharmaceuticals, Inc. Modulators of trex1

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2457895A1 (de) * 2004-07-12 2012-05-30 Idun Pharmaceuticals, Inc. Tetrapeptidanaloga
KR20080022092A (ko) 2005-06-08 2008-03-10 노파르티스 아게 유기 화합물
WO2007101347A1 (en) 2006-03-07 2007-09-13 Aegera Therapeutics Inc. Bir domain binding compounds

Also Published As

Publication number Publication date
CN101535273A (zh) 2009-09-16
BRPI0720050A2 (pt) 2014-10-14
KR20090086244A (ko) 2009-08-11
PL2099769T3 (pl) 2011-12-30
JP2010512321A (ja) 2010-04-22
EP2099769A1 (de) 2009-09-16
CA2670726A1 (en) 2008-06-19
US8048886B2 (en) 2011-11-01
US20110319614A1 (en) 2011-12-29
US20100249405A1 (en) 2010-09-30
MX2009005938A (es) 2009-06-17
PT2099769E (pt) 2012-08-31
AU2007332861A1 (en) 2008-06-19
CN101535273B (zh) 2012-04-11
RU2009125617A (ru) 2011-01-20
EP2099769B1 (de) 2011-07-27
ES2370536T3 (es) 2011-12-19
WO2008073305A1 (en) 2008-06-19

Similar Documents

Publication Publication Date Title
ATE517873T1 (de) 6-oxo-1,6-dihydropyrimidin-2-yle bei der behandlung proliferativer krankheiten
MX2009003834A (es) Derivados de pirrolidina como inhibidores de iap.
JO3007B1 (ar) مركبات و تركيبات كمثبطات كيناز بروتين
EA201070247A1 (ru) Ингибиторы протеасом
EA201100447A1 (ru) Органические соединения
EA201170521A1 (ru) Новые соединения
PH12012500674A1 (en) Heterocyclic compounds useful as pdk1 inhibitors
ATE522536T1 (de) Pyrrolopyrazin-kinasehemmer
EA201000100A1 (ru) Гетероциклические соединения, полезные в качестве ингибиторов mk2
GEP20146125B (en) Aminopyrimidines as syk inhibitors
UA108743C2 (uk) Похідні хіназолін-4(3н)-ону для застосування як інгібіторів рі3-кінази
MX2009013353A (es) Compuestos activadores de telomerasa y metodos para su uso.
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
PH12013500745A1 (en) Azaadamantane derivatives and methods of use
GEP20146131B (en) Carbazole compounds and therapeutic uses thereof
TW200942543A (en) Pyrrolopyrazine kinase inhibitors
NO20076371L (no) Fremgangsmate for fremstilling av fenoliske 4-bifenylylazetidin-2-oner
TNSN08227A1 (en) [4-(benzo [b] thi0phen-2-yl) pyrimidin-2yl] -amine derivatives as ikk-beta inhibitors for the treatment of cancer and inflammatory diseases.
EA200601391A1 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов
EA201170052A1 (ru) Производные тиофена или тиазола и их применение как ингибиторов pi3k
EA201000895A1 (ru) Композиции и способы для лечения лизосомных болезней
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
EA200801996A1 (ru) 2-замещенные производные 4-бензилфталазинонов в качестве гистаминовых h1- и h3-антагонистов
EA201170344A1 (ru) Азаиндольные ингибиторы iap
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2099769

Country of ref document: EP